AVITA Medical (RCEL) to Release Quarterly Earnings on Thursday

AVITA Medical (NASDAQ:RCELGet Free Report) will be announcing its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

AVITA Medical (NASDAQ:RCELGet Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). The firm had revenue of $15.20 million for the quarter, compared to analysts’ expectations of $15.04 million. AVITA Medical had a negative return on equity of 118.27% and a negative net margin of 92.04%. During the same period last year, the company posted ($0.41) earnings per share. On average, analysts expect AVITA Medical to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

AVITA Medical Stock Performance

RCEL opened at $10.39 on Thursday. The company has a quick ratio of 4.81, a current ratio of 5.29 and a debt-to-equity ratio of 1.71. The company has a market cap of $270.04 million, a price-to-earnings ratio of -5.90 and a beta of 1.54. AVITA Medical has a 52-week low of $7.51 and a 52-week high of $18.93. The firm’s fifty day simple moving average is $10.06 and its two-hundred day simple moving average is $9.25.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 price objective on shares of AVITA Medical in a report on Friday, August 9th.

Check Out Our Latest Research Report on AVITA Medical

About AVITA Medical

(Get Free Report)

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.

Further Reading

Earnings History for AVITA Medical (NASDAQ:RCEL)

Receive News & Ratings for AVITA Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA Medical and related companies with MarketBeat.com's FREE daily email newsletter.